SEC Filings

PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document


22 ER Hydrocodone Competitive Landscape • Currently, there are only two hydrocodone ER products on the market, Zohydro ® ER with BeadTek ® and Purdue’s Hysingla ® ER. Hysingla ® ER possesses Abuse Deterrent Labeling (“ADL”) (oral, intranasal and intravenous) • In February 2018, Purdue announced it would cease physician sales efforts related to its opioid portfolio, which includes Hysingla ® ER, leaving Zohydro ® ER with BeadTek ® as the sole actively marketed hydrocodone ER product on the market • Company believes Zohydro ® ER’s therapeutic profile, abuse deterrent technology and minimal hepatic impairment restrictions strongly positions the therapy among approved ER hydrocodones Product Stage Intranasal Intravenous Oral Dose Adjustment Mild / Moderate Impairment Monitoring Mild / Moderate Impairment Severe Impairment Severe Impairment Dosing Regiment ADL Claims Hepatic Impairment Restrictions Zohydro ® ER with BeadTek ® Marketed Q12 N/A N/A N/A None Yes None Yes Hysingla ® ER Not currently promoted (1) Q24 ✔️ None Yes None Yes ✔️ ✔️ (1) No longer actively promoted with healthcare professionals. ER Hydrocodone Competitive Landscape